Entasis Therapeutics to Present at H.C. Wainwright & Co. Global Life Sciences Conference in London
April 02 2019 - 8:00AM
Entasis Therapeutics Holdings Inc. (NASDAQ: ETTX), a clinical-stage
biopharmaceutical company focused on the discovery and development
of novel antibacterial products, today announced that Dr. Manos
Perros, President and Chief Executive Officer, will present at the
H.C, Wainwright & Co. Global Life Sciences Conference being
held April 7-9, 2019 in London, UK.
Details of the presentation are below:Event: H.C. Wainwright
& Co. Global Life Sciences ConferenceDate: Tuesday, April 9,
2019Time: 11:10 AM GMT / 7:10 AM EDT
In addition to his presentation, Dr. Perros will be hosting
1-on-1 investor meetings at the conference. Investors attending the
conference who are interested in meeting with Entasis management
should contact their H.C. Wainwright representatives.
About EntasisEntasis is a clinical-stage
biopharmaceutical company focused on the discovery, development and
commercialization of novel antibacterial products to treat serious
infections caused by multidrug-resistant Gram-negative bacteria.
Entasis’ targeted-design platform has produced a pipeline of
product candidates, including ETX2514SUL (targeting A. baumannii
infections), zoliflodacin (targeting Neisseria gonorrhoeae), and
ETX0282CPDP (targeting Enterobacteriaceae infections). Entasis is
also using its platform to develop a novel class of antibiotics,
non-β-lactam inhibitors of the penicillin-binding proteins (NBPs)
(targeting Gram-negative infections). For more information, visit
www.entasistx.com.
Entasis Company Contact
Kyle Dow Entasis Therapeutics (781) 810-0114
kyle.dow@entasistx.com
Investor Relations ContactLee RothThe Ruth
Group(646) 536-7012lroth@theruthgroup.com
Media ContactKirsten ThomasThe Ruth Group(508)
280-6592kthomas@theruthgroup.com
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Aug 2024 to Sep 2024
Entasis Therapeutics (NASDAQ:ETTX)
Historical Stock Chart
From Sep 2023 to Sep 2024